1585181-32-3

Upstream product

• 1333536-66-5 C₂₇H₂₉NO₂S 
• 1585181-12-9 pyrrolidine-1,2-dicarboxylic acid (2S)-2-[(1S,3S,5S)-1-tert-butyl-6-carboxy-5-(2,2,2-trichloroethoxycarbonyloxy)-3,6-dimethylhept-1-yl]ester 1-(9H-fluoren-9-ylmethyl)ester 
• 249507-22-0 (S)-N-methyl-N-methoxy-2-tert-butoxycarbonylamino-3-(triphenylmethylthio)propionamide 
• 158861-38-2 (R)-N-methyl-N-methoxy-2-tert-butoxycarbonylamino-3-(triphenylmethylthio)propionamide 
• 1333536-81-4 ethyl (S,E)-4-tert-butoxycarbonylamino-5-(triphenylmethylthio)-penta-2-enoate 
• 1094435-86-5 ethyl (S)-4-tert-butoxycarbonylamino-5-(triphenylmethylthio)pentanoate 
• 197454-20-9 (S)-5,5-dimethyl-4-hydroxyhexan-2-one 
• 630-19-3 pivalaldehyde 
• 67760-86-5 (3S)-2,2-dimethyl-5-hexen-3-ol 
• 612492-55-4 (S)-5,5-dimethyl-4-(tert-butyldimethylsilyloxy)hexan-2-one 
• 1585180-71-7 methyl (3S,5S,7S)-3-hydroxy-7-(4-methoxybenzyloxy)-2,2,5,8,8-pentamethylnonanoate 
• 1585180-73-9 (3S,5S,7S)-3-hydroxy-7-(4-methoxybenzyloxy)-2,2,5,8,8-pentamethylnonanoic acid 
• 1585180-75-1 allyl (3S,5S,7S)-3-hydroxy-7-(4-methoxybenzyloxy)-2,2,5,8,8-pentamethylnonanoate 
• 1585180-78-4 pyrrolidine-1,2-dicarboxylic acid (2S)-2-[(1S,3S,5S)-1-tert-butyl-6-allyloxycarbonyl-5-(2,2,2-trichloroethoxycarbonyloxy)-3,6-dimethylhept-1-yl]ester 1-(9H-fluoren-9-ylmethyl)ester 

Downstream Products

• 1585186-80-6 apratoxin S₁₀ 

Relevant academic research and scientific papers

MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT

The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.

Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity

Apratoxins are cytotoxic natural products originally isolated from marine cyanobacteria that act by preventing cotranslational translocation early in the secretory pathway to downregulate receptor levels and inhibit growth factor secretion, leading to pot